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1. Introduction  
Hepatitis B virus and rheumatoid arthritis 
More than one-third of the worldwide population is infected with hepatitis B virus (HBV), 
and 350 million individuals have chronic HBV infection [1], with 75% of those living in the 
Southeast Asia and Western Pacific regions. HBV infection is a leading cause of cirrhosis 
and hepatocellular carcinoma (HCC) [2] and is estimated to be responsible for 500,000–
700,000 deaths annually. Reactivation of hepatitis B in patients undergoing 
immunosuppressive therapy is a clinically important complication [3-5]. Hepatitis B 
reactivation can be transient and clinically silent but is often severe and results in acute 
hepatic failure. 
Two clinical scenarios contribute to the reactivation of hepatitis B. The first occurs in 
patients with chronic hepatitis B. Fulminant HBV has been reported in hepatitis B surface 
antigen (HBsAg)-positive patients with rheumatoid arthritis (RA) taking tumor necrosis 
factor agents (TNFA) [6, 7]. 
Second, reactivation of hepatitis B occurs in patients with resolved hepatitis B. In these 
patients, low levels of HBV replication have been shown to persist in the liver and in 
peripheral blood mononuclear cells for decades [8-10], and reactivation occurs after 
transplantation, immunosuppressive therapy, and allogeneic and autologous hematopoietic 
stem-cell transplantation, with the reappearance of HBsAg [11-15]. Reactivation of hepatitis 
B can occur in RA patients with resolved hepatitis B who are on immunosuppressive 
therapy, including corticosteroids (CS), methotrexate (MTX) [16], and TNFA [17,18], and can 
result in fulminant or lethal hepatitis [4]. Optimal management practices for this group of 
patients are unclear [9]. 
We performed this study to determine the rate of reactivation of HBV DNA replication in 
RA patients with resolved hepatitis B. 
2. Materials and methods 
2.1 Patients and methods 
In our departments, 516 patients who were treated for RA between January 2008 and 
August 2009 fulfilled the American College of Rheumatology 1987 revised criteria for RA. 
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All patients were evaluated for HBV markers, including HBsAg, anti-hepatitis B surface 
antibody (anti-HBs), and anti-hepatitis B core antibody (anti-HBc). HBV markers were 
detected using commercial enzyme immunoassays (HBsAg: ARCHITECT HBsAg QT, anti-
HBs: ARCHITECT Anti-HBs, and anti-HBc: ARCHITECT Anti-HBc; Abbott Laboratories, 
Wiesbaden, Germany). If patients were HBsAg-positive or HBsAg-negative and anti-HBs- 
and/or anti-HBc-positive, HBV DNA levels were assessed. Sensitivity was 2 log copies/mL. 
When negative HBV DNA results were obtained, measurements were repeated every 3 
months, and if HBV DNA became positive, measurements were repeated every month. 
Medications, including biologic agents, were generally not discontinued, irrespective of 
HBV DNA levels. All study protocols were approved by the ethics committees of the 
participating centers, and all patients provided written informed consent before enrolment. 
2.2 Quantification of HBV DNA in blood by real-time PCR 
HBV DNA levels were quantified using the automated COBAS TaqMan HBV Test version 
2·0 (Roche, Basel, Switzerland). Samples were pretreated using the COBAS AmpliPrep 
System for amplification and quantification by real-time PCR and were analyzed using the 
COBAS TaqMan gene analyzer [19]. 
2.3 Statistical analysis 
The Fisher’s exact test, Student’s t-test, and Mann–Whitney U test were used to compare 
baseline patient characteristics between subgroups. Two-tailed values of p ≤ 0.05 were 
regarded as significant. Cox regression hazard analyses were used to separately investigate 
the influence of biologic agents, MTX, CS, and disease-modifying antirheumatic drugs 
(DMARDs) on reactivation of HBV DNA replication. To identify the relative important of 
these factors, we performed a stepwise forward elimination multiple logistic regression 
model. All analyses were performed using JMP version 8.0 software (JMP Japan, Tokyo, 
Japan). 
3. Results 
Background characteristics of the 516 patients are listed in Table 1. Seven patients were 
HBsAg-positive, while 157 were HBsAg-negative and anti-HBs- and/or anti-HBc-positive 
(30.4%). No resolved hepatitis B patients were positive for HBV DNA at baseline. 
Subjects were followed for 18 months, and HBV DNA became positive (3.44 log copies/mL) 
in 13 of 157 patients (8.3%), whereas hepatic function remained normal in all cases (Table 1). 
Details of patients developing reactivation of HBV DNA replication are listed in Table 2; 1 
patient developed reactivation of HBV DNA replication twice, 10 patients showed HBV 
DNA replication during biologic agent therapy [etanercept (ETN), n = 8; abatacept, n = 2; 
adalimumab, n = 1; infliximab, n = 1; tocilizumab, n = 1; and rituximab, n = 1], whereas 3 
patient showed replication without biologic agent therapy. Types of DMARDs and 
immunosuppressants used for RA treatment during the study and numbers of patients 
being administered each pharmacotherapy are shown in Table 3. In 2 of the 13 patients, 
HBV DNA became negative without therapy. In 10 of the 13 patients, HBV DNA became 
negative with entecavir therapy (mean, 3.3 months). In the remaining 1 patient, after HBV 
DNA became positive, she suddenly died due to unknown causes. 
Exploratory analysis was conducted on factors that were potentially associated with HBV 
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Baseline demographic, clinical, 
and laboratory characteristics 
HBV replication (+) HBV replication (-) 
P 
value 
n 13 144  
Age, years (mean) 66.6 ± 10.7 (67.6) 64.9 ± 11.8 (66.2) 0.670 
Female, n 8 (61.5%) 114 (77.9%) 0.505 
RA duration, years 8.0 ± 7.7 (4.7) 7.6 ± 9.0 (4.0) 0.241 
CRP, mg/dL 0.92 ± 2.46 (0.09) 1.04 ± 2.11 (0.20) 0.218 
ESR, mm/h 26.0 ± 30.0 (13.0) 26.1 ± 26.8 (15.0) 0.476 
IgM RF, IU/mL 46.2 ± 34.0 (49.3) 88.0 ± 151.2 (24.5) 0.791 
AST, U/L 25.5 ± 6.5 (27.0) 27.9 ± 16.4 (23.0) 0.688 
ALT, U/L 19.9 ± 6.8 (20.5) 26.0 ± 19.2 (19.0) 0.959 
IgG, mg/dL 1454 ± 573 (1382) 1432 ± 450 (1358) 0.604 
Neutrophil count 3326 ± 1567 (2722) 4462 ± 2302 (3868) 0.063 
Lymphocyte count 1503 ± 425 (1431) 1732 ± 813 (1562) 0.323 
Values are given as mean ± standard deviation (median) 
RA, rheumatoid arthritis; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; Ig, 
immunoglobulin; RF, rheumatoid factor; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase 
Table 1. Comparison of hepatitis B virus (HBV) replication-positive and HBV replication-
negative patients for baseline demographic, clinical, and laboratory characteristics  
develop reactivation of HBV DNA replication, a significant difference was noted between 
the use of biologic agents (76.9% vs. 36.1%, respectively; p = 0.006), ETN (61.5% vs. 22.2%, 
respectively; p = 0.005), MTX (76.9% vs. 46.5%, respectively; p = 0.044), high-dose CS (15.4% 
vs. 1.4%; p = 0.035), and tacrolimus hydrate (30.8% vs. 5.6%; p = 0.010). Cox regression 
hazard analysis also revealed that biologic agent and ETN use can be as predictors for 
reactivation of HBV DNA replication. The hazard ratio (HR) for use of a biologic agent and 
etanercept was 10.9 (p = 0.008) and 6.9 (p = 0.001), respectively. Age at presentation, 
duration of RA, male gender, use of MTX and CS, dose of MTX and CS, levels of alanine 
aminotransferase and aspartate aminotransferase, immunoglobulin G level, neutrophil 
counts, and lymphoid cell counts were not associated with the reactivation of HBV DNA 
replication. The four variables extracted from the stepwise analysis were then entered as 
predictors of HBV DNA replication in a multivariate logistic regression model to determine 
their independent importance. The results of this model are shown in table 4. Predictive 
capacity was recognized for the use of tacrolimus hydrate only. 
A recent study investigated 244 HBsAg-negative lymphoma patients receiving cytotoxic 
chemotherapy [13]. Reactivation of hepatitis B developed following therapy in 8 of these 244 
patients (3.3%). Patients appeared to have a greater tendency to develop fulminant hepatic 
failure (3 of 8 patients, 37.5%). Direct DNA sequencing results confirmed that all 8 patients 
showed reactivation of hepatitis B from resolved hepatitis B. These patients were initially 
HBsAg-negative, and HBsAb- and/or HBcAb-positive, and serum liver enzyme levels were 
not elevated. At the time of hepatitis B reactivation, these patients became HBsAg positive. 
This change was associated with a more than 100-fold increase in serum HBV DNA levels, 
which occurred before the elevation of serum transaminases [13]. 
CD4+ T-helper cells may contribute to the control of HBV infection primarily by facilitating 








RA, rheumatoid arthritis; MTX, methotrexate; DMARDs, disease-modifying antirheumatic drugs; ALT, 
alanine aminotransferase 
aThis patient sequentially received 3 biologic agents: infliximab, etanercept, and tocilizumab. 
bThis patient had HBV-DNA reactivation twice. 
cThis patient sequentially received 2 biologic agents: etanercept, and abatacept. 
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Total 13 144   
Biologic agent 10 (76.9%) 52 (36.1%) 0.006 2.1 (1.5–3.1) 
 
Adalimumab 1 (7.7%) 8 (5.6%) 0.550 1.4 (0.2–10.2) 
Etanercept 8 (61.5%) 32 (22.2%) 0.005 2.8 (1.6–4.7) 
Infliximab 1 (7.7%) 17 (11.8%) 1.000 0.7 (0.1–4.5) 
Tocilizumab 1 (7.7%) 7 (4.9%) 0.507 1.6 (0.2–11.9) 
Abatacept 2 (15.4%) 3 (20.8%) 0.055 7.4 (1.4–40.3) 
Rituximab 1 (7.7%) 0 0.08  
Methotrexate 10 (76.9%) 67 (46.5%) 0.044 1.7 (1.2–2.3) 
mean dose 
7.1 ± 1.9 
mg/week 
6.8 ± 1.9 
mg/week 
0.707  
Corticosteroids 6 (46.2%) 57 (39.6%) 0.770 1.2 (0.6–2.2) 
mean dose 
12.7 ± 15.6 
mg/day 
5.7 ± 5.0 
mg/day 
0.533  





2 (1.4%) 0.035 
11.1 (1.7–
72.3) 
Sulfasalazine 1 (7.7%) 36 (25.0%) 0.303 0.3 (0.0–2.1) 
Bucillamine 3 (23.1%) 29 (20.1%) 0.729 1.1 (0.4–3.3) 
Tacrolimus hydrate 4 (30.8%) 8 (5.6%) 0.010 5.5 (1.9–15.9) 
Sodium aurothiomalate 1 (7.7%) 5 (3.5%) 0.410 2.2 (0.3–17.6) 
Leflunomide 1 (7.7%) 2 (1.4%) 0.230 5.5 (0.5–57.1) 
D-penicillamine 0 2 (1.4%) 1.000  
Actarit 0 1 (0.7%) 1.000  
Auranofin 0 7 (4.9%) 1.000  
Cyclosporine 0 1 (0.7%) 1.000  
Minocycline 
hydrochloride 
0 2 (1.4%) 1.000  
Cyclophosphamide 0 1 (0.7%) 1.000  
aValues are given as the number of patients taking a drug; patients can take more than one drug and 
can switch to another biologic agent 
HR, hazard ratio; 95% CI, 95% confidence interval 
Table 3. Number of patients using concomitant drugs related to rheumatoid arthritis during 











Tacrolimus hydrate 11.1 (2.0-50.6) 0.0015 
Sulfasalazine 0.3 (0.0-1.7) 0.2604 
Abatacept 1.5 (0.1-17.4) 0.7726 
immunoglobulin G 1.9 (0.0-160.3) 0.7572 
95% CI, 95% confidence interval 
Table 4. Logistic regression model predicting hepatitis B virus replication in rheumatoid 
arthritis patients 
tacrolimus hydrate may inhibit the function of CTL that controls HBV proliferation, and 
trigger reactivation of HBV-DNA replication [20, 21]. CS has shown to have direct 
stimulatory effects on HBV replication, in addition to indirect effects mediated via 
generalized immune system suppression [4]. 
TNF is a proinflammatory cytokine that plays a key role in host responses to several types of 
infection and other stimuli [22]. Various observations have strongly implicated TNF in the 
pathogenesis of RA and ankylosing spondylitis (AS), and increased TNF production 
propagates rheumatoid synovitis, promotes osteoclast formation, and results in 
characteristic bone and joint destruction [23]. TNFA significantly affects the current 
treatment of RA and AS [24] but is associated with adverse reactions such as reactivation of 
tuberculosis [25]. Studies regarding the safety of TNFA with chronic viral infection are 
limited. Several theories exist regarding how TNF inhibitors reactivate hepatitis B. Elevated 
TNF levels are seen in both the serum and hepatocytes of patients with chronic hepatitis B 
[26], and are secreted by HBV-specific CTL [27]. TNF has biological activity and an amino 
acid sequence similar to lymphotoxin, which inhibits HBV replication [28]. Infected cells are 
also reported to be selectively killed by TNF [33]. TNF acts to suppress HBV DNA 
replication by reducing intracellular HBV transcription [29]. Animal studies have shown 
that TNF-knockout mice have defects in the proliferative capacity of HBV-specific CTL [30], 
suggesting that TNF plays a role in clearing or controlling HBV [30, 31]. Moreover, HBV-
specific CTL inhibits HBV gene expression by secreting antiviral cytokines, such as 
interferon γ and TNF, and inducing apoptosis in HBV-infected hepatocytes [32, 33]. 
With increasing use of biologic agents such as TNFA, anti-IL-6 receptor, anti-CD20 [34], and 
anti-CD28, reactivation of HBV DNA replication in patients with resolved HBV will likely 
increase, particularly in endemic areas. Among patients who are scheduled to receive MTX, 
CS, tacrolimus hydrate, and biologic agents, patients who are HBsAg negative should be 
further screened for anti-HBc and anti-HBs. 
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